Analysts Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) PT at $43.88

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been given a consensus recommendation of “Moderate Buy” by the nineteen research firms that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $43.88.

TNDM has been the topic of several research analyst reports. Mizuho started coverage on shares of Tandem Diabetes Care in a report on Thursday, April 10th. They set a “neutral” rating and a $20.00 target price on the stock. Barclays reduced their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Royal Bank of Canada dropped their price target on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. The Goldman Sachs Group reduced their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, Sanford C. Bernstein lowered Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of institutional investors have recently modified their holdings of TNDM. Hood River Capital Management LLC bought a new position in shares of Tandem Diabetes Care during the fourth quarter worth approximately $46,035,000. Jacobs Levy Equity Management Inc. boosted its position in Tandem Diabetes Care by 189.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company’s stock valued at $59,830,000 after buying an additional 1,086,337 shares in the last quarter. Brown Advisory Inc. bought a new stake in shares of Tandem Diabetes Care during the fourth quarter worth $32,889,000. Park West Asset Management LLC increased its holdings in shares of Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company’s stock worth $57,632,000 after buying an additional 530,000 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its stake in shares of Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after acquiring an additional 523,843 shares during the last quarter.

Tandem Diabetes Care Trading Up 4.0 %

Shares of NASDAQ TNDM opened at $17.71 on Friday. Tandem Diabetes Care has a twelve month low of $15.75 and a twelve month high of $53.69. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -9.18 and a beta of 1.52. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The company’s fifty day moving average is $22.85 and its 200-day moving average is $30.55.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.